Table 2. Crude and adjusted prevalence ratios for eGFR (CKD-EPI) <60ml/min/1.73m2 at baseline.
| Covariate | Level | Crude | Adjusted | ||
|---|---|---|---|---|---|
| PR | 95% CI | PR | 95% CI | ||
| Sex | Female | ref | ref | ref | ref |
| Male | 0.95 | (0.90, 1.00) | 0.74 | (0.69, 0.79) | |
| Age Category | 17–24 years | ref | ref | ref | ref |
| 25–29 years | 1.36 | (1.17, 1.57) | 1.38 | (1.18, 1.62) | |
| 30–34 years | 1.71 | (1.48, 1.96) | 1.77 | (1.52, 2.04) | |
| 35–39 years | 2.37 | (2.07, 2.72) | 2.46 | (2.09, 2.89) | |
| 40–44 years | 3.20 | (2.79, 3.69) | 3.25 | (2.68, 3.93) | |
| 45–49 years | 4.33 | (3.75, 5.01) | 4.34 | (3.48, 5.40) | |
| 50–54 years | 5.83 | (5.02, 6.77) | 5.70 | (4.51, 7.20) | |
| 55–59 years | 7.64 | (6.51, 8.95) | 7.20 | (5.72, 9.07) | |
| 60–64 years | 9.54 | (8.00, 11.37) | 9.09 | (7.15, 11.55) | |
| 65+ years | 11.22 | (9.40, 13.40) | 10.18 | (7.83, 13.24) | |
| Hypertension Category | Hypotensive | 1.43 | (1.27, 1.60) | 1.35 | (1.18, 1.53) |
| Normotensive | ref | ref | ref | ref | |
| Pre-Hypertensive | 0.94 | (0.82, 1.07) | 0.92 | (0.81, 1.04) | |
| Hypertensive Stage I | 1.11 | (1.00, 1.22) | 1.03 | (0.94, 1.14) | |
| Hypertensive Stage II | 1.57 | (1.42, 1.74) | 1.23 | (1.11, 1.36) | |
| Severe Hypertension | 2.81 | (2.22, 3.54) | 1.63 | (1.34, 1.99) | |
| Unknown | 0.97 | (0.91, 1.04) | 1.04 | (0.95, 1.14) | |
| CD4 Cell Count | >500 | ref | ref | ref | ref |
| 351–500 | 1.00 | (0.89, 1.13) | 0.93 | (0.82, 1.05) | |
| 251–350 | 1.24 | (1.10, 1.40) | 1.11 | (0.97, 1.28) | |
| 100–250 | 1.62 | (1.45, 1.77) | 1.35 | (1.19, 1.52) | |
| <100 | 2.10 | (1.88, 2.35) | 1.72 | (1.48, 2.01) | |
| Unknown | 1.60 | (1.44, 1.77) | 1.43 | (1.25, 1.63) | |
Note: PR–prevalence ratio, CI–confidence interval, crude and adjusted analysis allow random effect at the facility level.